Overview

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Genentech, Inc.